Advanced Enzyme Technologies' stock experienced a significant 12% drop, closing at ₹428 during Monday's intra-day trading on the BSE. This decline occurred despite a generally firm market, as the company posted disappointing Q2 FY25 results.
The consolidated profit after tax decreased by 5% to ₹33.4 crore, compared to ₹35.2 crore in the same period last year, reflecting challenges in operational performance. This development has raised concerns among share market investment enthusiasts, particularly those tracking biotech sector trends.
At 11:18 AM, the company's stock was trading 11.5% lower at ₹429.65, contrasting with a 0.72% rise in the BSE Sensex. Notably, the stock had recently reached a 52-week high of ₹571.15 on September 16, 2024, making the decline even more striking.
Explore share market investment opportunities
The company reported a 7% year-on-year (YoY) revenue decline to ₹146 crore for Q2 FY25. This was largely driven by a 6% reduction in Human Nutrition revenue and a significant 31% de-growth in Bio-Processing income. In contrast, the Animal Nutrition and Specialized Manufacturing segments managed growth of 5% and 17%, respectively, showing resilience in specific areas.
Earnings before interest, tax, depreciation, and amortisation (EBITDA) fell 17% YoY to ₹42 crore, with margins contracting by 346 basis points to 29%. Despite a slight improvement in gross profit margins (up by 107 basis points to 77.6%), higher employee costs weighed heavily on overall profitability. These financial results have led many share market investment analysts to reassess their positions on Advanced Enzyme Technologies.
Geographical performance highlights
Geographical sales trends painted a mixed picture. While the U.S. market, accounting for 39% of the company’s revenues, posted a strong 21% YoY growth, other regions faced sharp declines. European sales dropped by 35%, Asia (excluding India) saw a 25% dip, and revenue from the rest of the world plunged by 49%. In India, which contributes 48% to the total revenue, sales fell by 15%.
Analysts suggest that this uneven performance may stem from logistical challenges, including delayed shipments or other operational issues. The company's inability to meet its double-digit growth target has further fueled investor scepticism in the share market investment landscape.
Future outlook and strategic focus
Despite these challenges, Advanced Enzyme Technologies remains optimistic about its future. The company is committed to strengthening its business model across three key divisions: Human Nutrition, Animal Nutrition, and Bio-Processing. It aims to develop and launch new products in these markets, particularly focusing on probiotics and enzymes, which have seen increasing demand.
The company is confident that its existing infrastructure and strategic investments will support its long-term growth. By leveraging these strengths, Advanced Enzyme hopes to regain investor confidence and solidify its position as a leader in the enzyme and probiotics industry.
Enzymes and probiotics: Key growth drivers
Enzymes and probiotics are crucial in various industries, including food and beverages, pharmaceuticals, and textiles. They play a significant role in maintaining gut health, which has been linked to improved immunity, better digestion, and overall well-being. As awareness about lifestyle diseases grows, so does the demand for these products.
Indian consumers, with rising disposable incomes and changing dietary preferences, are increasingly turning to functional foods and dietary supplements enriched with enzymes and probiotics. Analysts predict robust growth in this market, presenting significant opportunities for share market investment in the biotech and health sectors.
For android only